1 Min Read
Oct 18 (Reuters) - Pharma Mar SA :
* Completes patient recruitment for phase III trial with lurbinectedin (PM1183), CORAIL, for the treatment of platinum resistant ovarian cancer Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.